Literature DB >> 15388425

Antifungal therapy of murine Aspergillus terreus infection.

John R Graybill1, Steve Hernandez, Rosie Bocanegra, Laura K Najvar.   

Abstract

Aspergillus terreus is a species which is being seen increasingly frequently and which is highly resistant to amphotericin B in vitro and clinically. We evaluated amphotericin B, caspofungin, and posaconazole in a murine model of acute invasive aspergillosis. Caspofungin and posaconazole both appeared beneficial and may be reasonable treatment alternatives for infection with A. terreus.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15388425      PMCID： PMC521897          DOI： 10.1128/AAC.48.10.3715-3719.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Treatment of Scedosporium apiospermum brain abscesses with posaconazole.

Authors:  Ingo K Mellinghoff; Drew J Winston; Geoffrey Mukwaya; Gary J Schiller
Journal:  Clin Infect Dis       Date:  2002-05-16       Impact factor: 9.079

2.  Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole.

Authors:  A Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

Authors:  D A Sutton; S E Sanche; S G Revankar; A W Fothergill; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

4.  Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; S Nangia; J H Rex
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

5.  Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate.

Authors:  J C Bowman; G K Abruzzo; J W Anderson; A M Flattery; C J Gill; V B Pikounis; D M Schmatz; P A Liberator; C M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

6.  Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

7.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

8.  Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis.

Authors:  W E Sponsel; J R Graybill; H L Nevarez; D Dang
Journal:  Br J Ophthalmol       Date:  2002-07       Impact factor: 4.638

9.  The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.

Authors:  J C Bowman; P Scott Hicks; M B Kurtz; H Rosen; D M Schmatz; P A Liberator; C M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

Authors:  Qiu N Sun; Laura K Najvar; Rosie Bocanegra; David Loebenberg; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191
View more
  13 in total

1.  Efficacy of caspofungin against Aspergillus terreus.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Alfredo Santinelli; Annette W Fothergill; Stefania Fallani; Esther Manso; Eleonora Pisa; Daniele Giannini; Andrea Novelli; Maria I Cassetta; Teresita Mazzei; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 2.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

Review 3.  Host immune defense against Aspergillus fumigatus: insight from experimental systemic (disseminated) infection.

Authors:  I Mirkov; S Stosic-Grujicic; M Kataranovski
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

4.  Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans.

Authors:  J C Bowman; G K Abruzzo; A M Flattery; C J Gill; E J Hickey; M J Hsu; J Nielsen Kahn; P A Liberator; A S Misura; B A Pelak; T C Wang; C M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

Review 5.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 6.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

7.  In vitro activity and in vivo efficacy of posaconazole in treatment of murine infections by different isolates of the Aspergillus terreus complex.

Authors:  Valentina Salas; F Javier Pastor; M M Rodríguez; Enrique Calvo; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

Review 8.  Posaconazole.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Influence of amphotericin B and amphotericin B colloidal dispersion on the functions of human phagocytes in defence against Aspergillus species.

Authors:  S Perkhofer; G Blum; C Speth; A Mayr; M P Dierich; C Lass-Flörl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-06       Impact factor: 5.103

10.  Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs.

Authors:  V K Corrigan; A M Legendre; L J Wheat; R Mullis; B Johnson; D A Bemis; L Cepero
Journal:  J Vet Intern Med       Date:  2015-11-14       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.